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Background: Osteoclasts and osteoblasts regulate bone resorption and formation to allow bone remodeling and
homeostasis. The balance between bone resorption and formation is disturbed by abnormal recruitment of
osteoclasts. Osteoclast differentiation is dependent on the receptor activator of nuclear factor NF-kappa B (RANK)
ligand (RANKL) as well as the macrophage colony-stimulating factor (M-CSF). The RANKL/RANK system and RANK
signaling induce osteoclast formation mediated by various cytokines. The RANK/RANKL pathway has been primarily
implicated in metabolic, degenerative and neoplastic bone disorders or osteolysis. The central role of RANK/RANKL
interaction in osteoclastogenesis makes RANK an attractive target for potential therapies in treatment of osteolysis.
The purpose of this study was to assess the effect of inhibition of RANK expression in mouse bone marrow
macrophages on osteoclast differentiation and bone resorption.
Methods: Three pairs of short hairpin RNAs (shRNA) targeting RANK were designed and synthesized. The optimal
shRNA was selected among three pairs of shRNAs by RANK expression analyzed by Western blot and Real-time PCR.
We investigated suppression of osteoclastogenesis of mouse bone marrow macrophages (BMMs) using the optimal
shRNA by targeting RANK.
Results: Among the three shRANKs examined, shRANK-3 significantly suppressed [88.3%] the RANK expression
(p < 0.01). shRANK-3 also brought about a marked inhibition of osteoclast formation and bone resorption as
demonstrated by tartrate–resistant acid phosphatase (TRAP) staining and osteoclast resorption assay. The results of
our study show that retrovirus-mediated shRANK-3 suppresses osteoclast differentiation and osteolysis of BMMs.
Conclusions: These findings suggest that retrovirus-mediated shRNA targeting RANK inhibits osteoclast
differentiation and osteolysis. It may appear an attractive target for preventing osteolysis in humans with a potential
clinical application.
Keywords: RANK, Inhibition, RNA interference, Cell cultureBackground
Osteoclasts promote bone resorption in metabolic, de-
generative and neoplastic bone disorders. Clinically, the
mechanisms inhibiting osteoclast formation are poten-
tially important for preventing bone resorption in these
bone disorders. Recent studies on cellular and molecular
interactions leading to osteolysis have demonstrated a
critical role for the receptor activator of nuclear factor
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reproduction in any medium, provided the orand its ligand (RANK/RANKL) [1]. RANKL is expressed
on the surface of stromal cells and osteoblasts. It binds
to RANK which is expressed on osteoclast progenitors
to induce and promote further differentiation into mature
osteoclasts [2]. Stromal cells/ osteoblasts also secrete
osteoprotegerin (OPG), a soluble glycoprotein of the
tumor necrosis factor receptor super-family. OPG acts
as a decoy receptor for RANKL, competing against
RANK and thereby inhibiting osteoclast differentiation
[3]. In addition, the macrophage colony-stimulating factor
(M-CSF) is also produced by stromal cells and induces
RANKL-like effects in osteoclasts. It is essential for the
survival and proliferation of macrophages and the regula-
tion of osteoclastogenesis [4]. Furthermore, various cyto-
kines or hormones influence the complex osteoclast. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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CSF and OPG on stromal cells or osteoblasts [5].
However, the function of RANK is not limited to cell
differentiation. As a member of the tumor necrosis fac-
tor receptor (TNFR) family RANK is expressed on the
surface of osteoclast progenitor cells and plays an im-
portant role in bone homeostasis. RANK transduces
intracellular signals upon ligand binding by recruiting
various adaptor proteins through specific motifs in the
cytoplasmic domain [5-11]. Thus, the central role of
RANK/RANKL interaction in osteoclastogenesis makes
RANK an attractive target for potential therapies.
The aim of this study was to assess the effect of inhib-
ition of RANK expression in mouse bone marrow macro-
phages (BMMs) on osteoclast differentiation and bone
resorption. We also studied the extent of osteoclast inhib-
ition by targeting RANK with retrovirus-mediated shRNA.
Methods
Isolation and culture of bone marrow macrophages
All experimental procedures involving animals were per-
formed in compliance with the regulations of the Guide
for the Care and Use of Laboratory Animals (NIH publica-
tions Nos. 80–23, revised 1996). Furthermore, the proce-
dures complied with the institutional ethical guidelines for
animal experiments and approval was received from the
institutional review board.
The femora of 5-week-old BALB/c mice fresh cadavers
were aseptically removed and dissected free of adhering
tissues. The bone ends were cut off with scissors and the
marrow cavity was flushed slowly by injecting Dulbecco's
Modified Eagle’s Medium (DMEM; Invitrogen, Carlsbad,
CA). The bone marrow cells were harvested from one
end using a sterile needle. 5 × 106 of these cells were
adhered to tissue culture dishes in 10 ml of DMEM
containing 10% fetal bovine serum (FBS; Gibico, BRL,
Germany), 100 IU/ml penicillin G (Gibico) and 100 μg/
ml streptomycin (Gibico) with 100 ng/ml M-CSF
(PerproTech, London, UK). Three days later, the floating
cells were removed and the attached cells were harvested
by treatment with phosphate buffer solution (PBS) and
used as bone marrow macrophages (BMMs).
CD14 and CD34 immunohistochemistry of BMMs
The sections adhered with cells were harvested and
washed with PBS, fixed with 95% ethanol for 30 minutes
at 25°C, and then washed three times with cold PBS.
The sections were placed in a pressure cooker for anti-
gen retrieval using citrate buffer pH6 for 10 minutes.
They were then incubated at room temperature and
washed with distilled water. After washing, the sections
were placed in hydrogen peroxidise 3% for 6 minutes to
block endogenous peroxide, washed with water three
times and finally with Tris-buffered saline (TBS) for10 minutes to eliminate non-specific staining. The ex-
cess TBS was removed from the slides before incubation
with primary antibody.
The immunohistochemical procedure and prepar-
ation of controls were carried out according to the
manufacturing company’s standards and guidelines.
The controls were used to assess the specificity of the
reaction as follows: pre-incubation of the cells with the
peptide in order to obtain the first antibody, incuba-
tion of the cells with an irrelevant primary antibody of
the same isotype followed by the second antibody. The
sections were incubated with the primary antibodies
(CD14 (Santa Cruz, CA, USA, sc-73794) [1:250] and
CD34 (Santa Cruz, sc-7045) [1:250]) for 30 minutes at
room temperature, washed with TBS and incubated
with link antibody for 15 minutes each. Then the
sections were washed with TBS and incubated with
labeled Streptavidin-biotin (LSAB) for 15 minutes at
room temperature, washed again with TBS and incu-
bated with diaminobenzidine (DAB) and substrate
chromogen system for 5 minutes at room temperature
which resulted in brown-coloured precipitates at the
antigen site (Figure 1A-B).
Cloning into retroviral vectors, selection of the optimal
shRNA and stable infection
RANK small hairpin RNA (shRNA) was designed and
cloned into the pSUPER-retro-puro retroviral vector
(Oligoengine, Seattle, Wash., USA). Three shRNAs were
chosen based on the sequence of the mouse RANK gene
(GenBank gi: NM_ 009399). They covered different
regions of the RANK sequence and showed no hom-
ology with non-RANK sequences. A scrambled shRNA
was used as a control. The target sequences and corre-
sponding oligonucleotide sequences for the four
shRNAs, designated shRANK-1, shRANK-2, shRANK-3
and scramble shRNA, are shown in Table 1. Transfec-
tion of cells was carried out with Lipofectamine 2000TM
reagent (Invitrogen). Control cells were treated with
pSUPER-retro-puro retroviral vector. The relative RANK
mRNA and protein levels were determined by Real-time
polymerase chain reaction (RT-PCR) and Western blot
analyses respectively. The optimal shRANK or vector
plasmid and the packaging plasmid PIK were transfected
into 293FT cells using the calcium phosphate precipita-
tion method [12,13]. Competent retroviruses were col-
lected 48 hours after transfection. The retroviruses
harboring shRANK were transfected into BMMs. Subse-
quently, the cells were passaged and harvested after
treatment in 0.625 μg/ml puromycin (Sigma, St. Louis ,
USA) medium for three days. Meanwhile, pSUPER-GFP-
retro-puro retroviral vector was used to generate
shRANK retrovirus. After transfection, BMMs were pas-
saged and purified by puromycin. The effect of gene
Figure 1 CD14 (A) and CD34 (B) immunohistochemistry of isolated bone marrow macrophages (BMMs).
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sion with fluorescence microscopy.
Isolation of RNA and real time RT-PCR analysis
Total RNA was isolated from cultured cells and purified
using the RNeasy Mini Kit (Qiagen, Hilden, Germany).
The yield and purity of the RNA was controlled photo-
metrically. RT-PCR was performed in the ABI PRISMW
7000 Sequence Detection System (Applied Biosystems,
Foster, USA) using the SYBR Green I master Mix
(Applied Biosystems) according to the manufacturer’s
instructions. RT-PCR of Glyceraldehyde-3-Phosphate
Dehydrogenase (GAPDH), a housekeeping gene, served
as a control. Primers used in this study were as follows:
GAPDH, 5’- CCAATGTGTCCGTCGTGGAT-3’ (for-
ward) and 5’- TGCTGTTGAAGTCGCAGGAG -3’ (re-
verse); RANK, 5’ -CTGCCTCTGGGAACGTGACT -3’
(forward) and 5’- GCGAGGTCTGGCTGACATAC-3’
(reverse). Two pairs of primers were added in the action
tube for RT-PCR. The PCR cycle conditions were as fol-
lows: 2 minutes at 95°C, 30 seconds at 95°C, 35 seconds
at 60°C, 40 cycles of 15 seconds at 95°C and 30 seconds
at 60°C. Each PCR procedure included a negative control
reaction without a template.
Western blot analysis
The cells were washed three times with ice-cold PBS
and lysed in RIPA lysis buffer (Sigma, St. Louis, MO,Table 1 Target sequences and corresponding oligonucleotide
shRANK-2, shRANK-3 and scramble shRNA
shRNA Target sequences Oligonucleotide sequen
shRANK-1 caagaagtgtgtgaaggta Forward: 5’- -3’ GATCCCC
Reverse:5’- -3’ AGCTTAAA
shRANK-2 tgggcttcttctcagatgt Forward: 5’- -3’ GATCCCC
Reverse: 5’- -3’ AGCTTAAA
shRANK-3 gcgctgacagctaatttgt Forward: 5’- -3’ GATCCCC
Reverse: 5’- -3’ AGCTTAAA
scrambled shRNA Forward: 5’- -3’ GATCCCC
Reverse: 5’- -3’ AGCTTAAAUSA). The lysates with Sodium dodecyl sulphate (SDS)
buffer were boiled for 5 minutes and separated by 10%
SDS polyacrylamide gel electrophoresis (SDS-PAGE).
They were then transferred to a 0.45 μm polyvinylidene
difluoride membrane (PVDF; Millipore, Bedford, USA)
and incubated with RANK antibodies (Santa Cruz, CA,
USA) at a dilution of 1/3000 and Horseradish peroxidase
(HRP)-conjugated goat anti- rabbit antibody (Santa
Cruz) at a dilution of 1/6000. The HRP substrate was
observed on the PVDF membrane. After three washes,
the PVDF membrane was incubated with β-actin anti-
body (Santa Cruz) and HRP-conjugated antibody. The
HRP substrate was observed again. For densitometric
analyses, blots were scanned and quantified using Quan-
tity One analysis software (Bio-Rad, Hercules, USA),
and the results were expressed as the percentages of
β-actin immunoreactivity.
In vitro osteoclastogenesis assays and bone resorption
assay
BMMs or retrovirally infected BMMs were cultured in
24-well tissue culture plates (5 × 104 cells/well) in DMEM
containing 10% FBS in the presence of 30 ng/ml M-CSF
and 100 ng/ml RANKL (PeproTech, London, UK). Osteo-
clastogenesis began on the sixth day and the cultures
were stained for tartrate-resistant acid phosphatase
(TRAP) on the ninth day using a kit (Sigma, St. Louis,
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Only TRAP-positive cells with more than three nuclei
were counted optically. The values were expressed as
means and standard deviations of triplicate cultures. Bone
resorption assays were performed using osteoclasts gener-
ated on mice bone slices from infected or uninfected
BMMs as described previously. The bone slices were har-
vested on the ninth day. Osteoclastic resorption was
quantified by measuring the area of resorption pits with
digital image analysis software (Image-pro plus 6.0, Media
Cybernetics, USA). The percentage of resorption was cal-
culated by dividing the resorbed area by the total area of
the imaged bone slice surface.
Statistical analysis
Data are expressed as mean ± standard deviation. The
statistical significance of differences between the experi-
mental and the control groups was evaluated by inde-
pendent Student’s t test. Differences between the groups
of the optimal shRANK selection were analyzed using
analysis of variance (ANOVA) with SPSSW 16.0 software
(SPSS Inc, Chicago, IL). P <0.05 was considered to be
statistically significant.
Results and discussion
As shown in Figure 1, nearly all cultured BMMs
expressed the monocyte/macrophage surface markers
CD14 (94.3-0.4%) and CD34 (90.6-3.5%). BMMs also
expressed CD11b (94.8-2.9%) and F4/80 (93.1-3.0%),
which were the special surface markers of monocyte/
macrophage [14]. Flow cytometric analysis on day 7
showed similar patterns of surface marker expression
(data not shown).Figure 2 RANK gene expression inhibited by shRNAs and the inhibitio
pSuper-retro-puro; lane 2: pscrambled shRNA; lane 3: psh RANK-1; lane 4: pRANK mRNA inhibition by RT-PCR
The inhibition rates of pshRANK-1, pshRANK-2 and
pshRANK-3 were 43.4%, 57.3% and 65.8% (p < 0.01)
respectively compared with the control plasmid pSUPER-
retro-puro (Figure 2).
RANK protein inhibition by Western blot
The inhibition rates of pshRANK-1, pshRANK-2 and
pshRANK-3 were 59.4%, 63.3% and 88.3% (p < 0.01) re-
spectively compared with the control plasmid pSUPER-
retro-puro (Figure 3).
Stable silencing of the RANK in BMMs by retrovirus-
mediated shRNA
Subsequently, the effect of shRANK-3 on infected BMMs
was studied to determine the biological influence of
RANK on osteoclastogenesis in BMMs. Western blot was
used to evaluate inhibition of RANK expression in stable
cells. Expression was reduced by about 80.7% (p < 0.01),
as compared with uninfected BMM cells (Figure 4). Mean-
while, the levels of RANK protein were significantly
reduced in the 3rd-passage cells, which were used in all
experiments in this study. The expression of GFP was
continuously monitored with fluorescence microscopy to
test whether the cells stably express GFP-retro-puro
retrovirus. The 10th-passage cells were detected to stably
express GFP protein.
RANK silencing in BMMs abolishes osteoclast
differentiation and osteolysis
We performed functional assays to determine the effect
of RANK inhibition on osteoclast differentiation and oste-
olysis. Infected BMM cells or BMM cells were treatedn rate of psh RANK-1, psh RANK-2 and psh RANK-3. Lane 1:
sh RANK-2; lane 5: psh RANK-3.
Figure 3 Western blot for RANK (A) and the inhibition rate of psh RANK-1, psh RANK-2 and psh RANK-3 (B) in BMMs. Figure 1 RANK
gene expression inhibited by shRNAs and the inhibition rate of psh RANK-1, psh RANK-2 and psh RANK-3. Lane 1: Psuper-retro-puro; lane 2:
pscrambled shRNA; lane 3: psh RANK-1; lane 4: psh RANK-2; lane 5: psh RANK-3.
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additional nine days and subjected to TRAP staining and
osteoclast resorption assay. TRAP+ cells with more than
three nuclei were counted and the area of osteoclast
resorption was measured with a scanning electron micro-
scope (SEM). We noted a reduction in the number of TRAP
+ multinucleated cells in infected BMMs (6.8 ± 1.64) com-
pared with BMMs (82 ± 4.64) (p < 0.05) (Figure 5 A-C).
Furthermore, a significant reduction in resorption areas
on the bone slices (Figure 5 D-F) in infected BMMs
(16.6% ± 2.70%) compared with BMMs (2.8% ± 0.84%)
(p < 0.05) was observed, indicating profound inhibition
of osteoclastic bone resorption. Meanwhile, the resorp-
tion area of bone slices between untreated and treated
BMM cells was evaluated by Scanning Electron Micros-
copy (Figure 5 G, H). The difference is obvious.
Discussion
Osteoclasts (OCs) are multinucleated cells derived from
circulating osteoclast precursor cells (OCPs) of themonocyte/macrophage lineage. They represent the only
cell type capable of bone resorption [5]. Osteoclasts pro-
mote bone resorption in metabolic, degenerative and
neoplastic bone disorders. Excess osteoclast activity in
osteolysis may involve not only generation and activation
of OCs, but also increased recruitment of OCPs. The
increased bone resorption in osteolysis is thought to be
mediated via numerous pro inflammatory cytokines.
These cytokines are considered to act primarily via a
common final pathway involving members of the TNF
receptor-ligand family: The RANKL and its correspond-
ing RANK receptor that play a crucial role in osteoclast
differentiation and activation, and OPG, the physio-
logical inhibitor of RANKL [15]. In turn, excess osteo-
clast activity is associated with the disorders of the TNF
receptor-ligand family that ultimately lead to metabolic,
degenerative and neoplastic bone disorders. Clinical
treatments are needed that can inhibit excess osteolysis
in an inflammatory microenvironment. Given that
RANK is the essential signaling receptor for osteoclast
Figure 4 RANK silencing in BMMs by stable transduction by
retroviruses. BMMs stably transduced with shRNA against the RANK
were analyzed for RANK protein levels by Western blot (A, B); β-actin
served as a loading control.
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hypotheses that inhibition of RANK expression by RNA
silencing would reduce the number of osteoclasts and
the activity of bone erosion.
The limitation of our study is that BMMs culture
experiments have a limited perspective of time as we
analyzed the BMM cells for only nine days. As meta-
bolic, degenerative and neoplastic bone disorders are
processes which can take years, the reactions by osteo-
clasts might change in the course of time. The correl-
ational research in vivo should be carried on in future
studies. Nevertheless, we demonstrated that the differ-
ence in osteoclast number and bone erosion between
the study groups was significant.
Our data showing inhibition of RANK expression
by successful silencing of RNA, which can inhibit spe-
cific gene expression, suggests that we can obtain the
optimal shRNA-silencing RANK. The inhibition rates of
pshRANK-1, pshRANK-2 and pshRANK-3 by Western
Blot were 59.4%, 63.3% and 88.3% (p < 0.01) respectively
compared with the control plasmid pSUPER-retro-puro,
which is consistent with the result of Real-time PCR.
Thus, shRANK-3 was identified as the optimal sequence
silencing RANK.
Our study shows that inhibition of RANK expres-
sion suppresses osteoclast differentiation, thus leadingto reduction of bone resorption. We found that RANK
gene-silencing using retrovirus-mediated shRNA can
significantly suppress RANK expression of BMMs. The
inhibition rates of RANK protein by Western Blot was
about 80.7% (p < 0.01). TRAP staining and SEM reveal
that the osteoclastogenesis of infected BMMs is signifi-
cantly reduced, compared with uninfected BMMs.
We are not aware of any study showing a similar effect
of retrovirus-mediated gene therapy with pshRANK on
osteoclastogenesis in BMMs. Although OPG fusion pro-
tein and OPG have been used successfully to prevent
osteolysis, OPG may bind TNF related apoptosis-
inducing ligand in addition to RANKL and thus act as a
cancer survival factor [16-18]. Clinical trials with a
monoclonal antibody against RANKL showed efficacy
and anti-resorptive activity [19], but sensitization to
monoclonal antibodies` therapeutics poses significant
risk to the patient and may blunt the efficacy of these
therapies [20]. In addition, antibodies against OPG
fusion protein harbor the potential risk of cross-reacting
with and neutralizing endogenous OPG.
Numerous studies have shown that the RANK/
RANKL pathway is central to cellular and molecular
mechanisms associated with the process of osteolysis
[4,15,18].
Subsequently, a gene-silenced RANK gene leads to an
imbalance of a variety of downstream signaling path-
ways which are required for osteoclast development
[21]. RANKL binding to RANK induces the trimeriza-
tion of RANK and TNF receptor-associated factors 6
(TRAF6), which leads to the activation of mitogen-
activated kinases (MAPK). TRAF6 adaptor protein binds
to the intracellular part of the activated RANK receptor
and starts the NF-κB pathway, which finally leads to
activation of osteoclastogenesis [22]. Different members
of the MAPK family, such as p38-MAPKα and p38-
MAPKβ, are known to be involved in osteoclastogenesis
[23]. Involvement of p38 mitogen-activated protein kin-
ase signaling pathway in osteoclastogenesis is mediated
by receptor activator of NF-κB ligand (RANKL) [23].
Furthermore, an influence on bone metabolism is caused
by the induction of the phoshatidylinositol (PI) metabol-
ism, which is mediated by the c-Src kinase. The targeted
disruption of the c-Src proto-oncogene leads to osteope-
trosis in mice [24]. Following notable advances in the
understanding of intracellular signaling pathways of
RANK, therapeutic drugs specifically targeting down-
stream signaling molecules have been developed includ-
ing Interferon-β, γ, p38 inhibitor (SB203580, FR167653),
JNK inhibitor (SB600125), IKappaB kinase (IKK) and
NEMO binding domain (NBD peptide) inhibitor, NF-κB
inhibitor (NF-κB decoy), Calcineurin inhibitor (Cyclo-
sporin A, FK 506), NFAT inhibitor (VIVIT peptide),
PI3K inhibitor (Wortmannin, LY290442) [25-30]. The
Figure 5 Inhibition of osteoclastogenesis by RANK silencing. (A, B) Osteoclast differentiation of BMMs as identified by TRAP staining.
(C) Quantification of the data. The multinucleated TRAP-positive cells (>3 nuclei) in eight random view areas (at 200× magnification) in
each of the five replicates were counted. Osteoclast resorption was quantified using toluidine blue staining (at 400× magnification) (D,E,F).
Comparison of the resorption area of bone slices between untreated and treated BMM cells was evaluated by Scanning Electron Microscopy
(at 400× magnification) (G, H).
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city of these compounds, since these intracellular signal-
ing pathways are also important for the function and
homeostasis of other cells and tissues. Furthermore,
RANK is expressed by other types of cells (inflammatory
cells and endothelial cells) and plays a role in other
physiological processes such as inflammation and angio-
genesis. This requires the development of a sophisticated
cell-specific or tissue-specific drug delivery system to
prevent or mitigate their adverse effects [31].
RANK suppression in the RANKL/RANK system
appears to be a promising target for potential therapies
in the treatment of osteolysis. RNA interference to
inhibit specific gene expression has been shown to be
an effective and promising technology for both basic
science research and therapeutic intervention [32,33].
Conclusions
Our results suggest that retrovirus-mediated pshRANK
suppresses RANK expression of BMMs which further
inhibits osteoclastogenesis of BMM treated with M-CSF
and RANKL. These findings may provide novel thera-
peutic strategies for the management of osteolysis. Safety
and ethics are areas of concern for employing thistherapeutic intervention in humans. In future studies,
we would like to investigate the effects of retrovirus-
mediated pshRANK on the inhibition of osteoclast dif-
ferentiation and osteolysis in vivo.
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